Pseudotumor cerebri with or without venous sinus thrombosis is a rare clinical presentation of Behçet disease in childhood. We present here a case of childhood pseudotumor cerebri without a previous diagnosis of Behçet disease. The detailed history and physical examination of the case led to the diagnosis of neuro-Behçet disease. The investigation of predisposition to thrombosis revealed heterozygous factor V Leiden mutation along with the high lipoprotein(a) level. The symptoms resolved dramatically by treatment with the combination of immunosuppression and anticoagulation with regard to the detected factor V Leiden mutation and high lipoprotein(a) level. After a symptom-free period of 9 months, the cerebral vein thrombosis recurred. We present this case to draw attention to this rare cause of pseudotumor cerebri in childhood and to emphasize the importance of additional thrombotic risk factors regarding the potential recurrence of thrombotic events in Behçet disease.
Warman R.Management of pseudotumor cerebri. Int Ped. 2000; 3:147-150.
2.
Johnston I., Owler Brian, Pickard J.The Pseudotumor Cerebri Syndrome: Pseudotumor Cerebri, Idiopathic Intracranial Hypertension, Benign Intracranial Hypertension, and Related Conditions. New York: Cambridge University Press; 2007.
3.
Gordon K.Pediatric pseudotumor cerebri: descriptive epidemiology. Can J Neurol Sci. 1997;24(3):219-221.
4.
Behcet H.Uber residivierende, aphtose durch ein Virus verursachtes Geschwure am Mund, am Auge und an der Genitalien. Derm Wschr. 1937;105:1152-1157.
5.
Evaluation of diagnostic (‘classification’) criteria in Behçet’s disease: towards internationally agreed criteria . The International Study Group for Behçet’s Disease. Br J Rheumatol. 1992;31(5): 299-308.
6.
Siva A., Altintas A., Saip S.Behçet’s disease and the nervous system. Curr Opin Neurol. 2004;17(3):347-357.
7.
Kone-Paut I. , Chabrol B., Riss JM, et al. Neurologic onset of Behçet’s disease: a diagnostic enigma in childhood. J Child Neurol . 1997;12:237-241.
8.
Cavara V., D’ Emro E.A case of Neuro-Behçet’s syndrome. Acta XVIII Concili Ophtalmologici. 1954;3:1489.
9.
Tursen U., Gurler A., Boyvat A.Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet’s disease. Int J Dermatol. 2003;42(5):346-351.
10.
Farah S., Al-Shubaili A., Montaser A., et al. Behçet’s syndrome: a report of 41 patients with emphasis on neurological manifestations. J Neurol Neurosurg Psychiatry. 1998;64(3):382-384.
11.
Kural-Seyahi E., Fresko I., Seyahi N., et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore ). 2003;82(1):60-76.
12.
Al-Araji A., Kidd DPNeuro-Behçet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009; 8(2):192-204.
13.
Akman-Demir G. , Serdaroglu P., Tasci B.Clinical patterns of neurological involvement in Behcet’s disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain. 1999;122(11): 2171-2182.
14.
Al-Araji A. , Sharquie K., Al-Rawi Z.Prevalence and patterns of neurological involvement in Behcet’s disease: a prospective study from Iraq. J Neurol Neurosurg Psychiatry. 2003;74(5):608-613.
Serdaroğlu P.Behçet’s disease and the nervous system. J Neurol. 1998;245(4):197-205.
17.
Lin A., Foroozan R., Danesh-Meyer HV, De Salvo G., Savino PJ, Sergott RCOccurrence of cerebral venous sinus thrombosis in patients with presumed idiopathic intracranial hypertension. Ophthalmology. 2006;113(12):2281-2284.
18.
Tibussek D. , Schneider DT, Vandemeulebroecke N., et al. Clinical spectrum of the pseudotumor cerebri complex in children. Childs Nerv Syst.2010;26(3):313-321.
19.
Ozoran K., Dugun N., Gurler A., et al. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet’s disease. Scand J Rheumatol. 1995;24(6):376-382.
20.
Kayikcioglu M., Aksu K., Hasdemir C., et al. Endothelial functions in Behcet’s disease. Rheumatol Int. 2006;26(4):304-308.
21.
Yalcindag FN , Batioglu F., Ozdemir O., et al. Soluble endothelial protein C receptor levels in Behcet patients with and without ocular involvement. Graefes Arch Clin Exp Ophthalmol. 2008; 246(11):1603-1608.
22.
Gurgey A., Balta G., Boyvat A. Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet’s disease. Blood Coagul Fibrinolysis . 2003;14(2): 121-124.
23.
Orem A., Deger O., Memis O., et al. Lp(a) lipoprotein levels as a predictor of risk for thrombogenetic events in patients with Behçet’s disease. Ann Rhem Dis. 1995;54(9):726-729.
24.
Gozdasoglu S., Uysal Z., Ertem M., Akar N.Three risk factors- high lipoprotein (a), elevated FVIII, and FV Leiden-in a pediatric Behçet’s disease patient with deep vein thrombosis. Thromb Res. 2002;105(2):125-133.
25.
Can E., Kara B., Somer A., et al. Neuro-Behçet disease presenting as secondary pseudotumor syndrome: case report. Eur J Ped Neurol. 2006 ;10(2):97-99.
